Stereoselective Disposition of S- and R-Licarbazepine in Mice by Alves, Gilberto et al.
Stereoselective Disposition of S- and R-Licarbazepine in Mice
GILBERTO ALVES,1 ISABEL FIGUEIREDO,1 AMI´LCAR FALCA˜O,1* MARGARIDA CASTEL-BRANCO,1
MARGARIDA CARAMONA,1 AND PATRI´CIO SOARES-DA-SILVA2
1Faculty of Pharmacy, Laboratory of Pharmacology, Coimbra University, Coimbra, Portugal
2Department of Research and Development, BIAL, S. Mamede do Coronado, Portugal
ABSTRACT The stereoselective disposition of S-licarbazepine (S-Lic) and R-licar-
bazepine (R-Lic) was investigated in plasma, brain, liver, and kidney tissues after their
individual administration (350 mg/kg) to mice by oral gavage. Plasma, brain, liver, and
kidney concentrations of licarbazepine enantiomers and their metabolites were deter-
mined over the time by a validated chiral HPLC-UV method. The mean concentration
data, attained at each time point, were analyzed using a non-compartmental model. S-Lic
and R-Lic were rapidly absorbed from gastrointestinal tract of mouse and immediately
distributed to tissues supplied with high blood flow rates. Both licarbazepine enantio-
mers were metabolized to a small extent, each parent compound being mainly responsi-
ble for the systemic and tissue drug exposure. The stereoselectivity in the metabolism
and distribution of S- and R-Lic was easily identified. An additional metabolite was
detected following R-Lic administration and S-Lic showed a particular predisposition for
hepatic and renal accumulation. Stereoselective processes were also identified at the
blood–brain barrier, with the brain exposure to S-Lic almost twice that of R-Lic. Another
finding, reported here for the first time, was the ability of the mouse to perform the chi-
ral inversion of S- and R-Lic, albeit to a small extent. Chirality 20:796–804,
2008. VC 2008 Wiley-Liss, Inc.
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It is widely known that enantiomers of chiral drugs may
have different pharmacodynamic, pharmacokinetic and
toxicological effects upon biological systems.1,2 Differ-
ences in the biological activity may be intrinsically related
to the pharmacodynamics of each enantiomer or may be
due to differences in their pharmacokinetics, with different
blood or tissue concentration-time profiles. It is generally
accepted that the drug metabolism introduces the greatest
degree of chiral discrimination in pharmacokinetic pro-
cesses, although other mechanisms in the body, among
which the absorption, protein and tissue binding, distribu-
tion and excretion, may also contribute to the stereoselec-
tive drug disposition.3–6 Hence, chirality has emerged as a
critical issue in drug design, since the regulatory agencies
now require pharmacological and toxicological studies not
only on the racemate but also on both enantiomers before
granting approval of a new chiral drug.2
Eslicarbazepine acetate (ESL), or S-licarbazepine ace-
tate, previously known as BIA 2-093, is a new chiral drug
currently undergoing clinical development for the treat-
ment of epilepsy.7 The molecule of licarbazepine acetate
contains a chiral center at the tenth position, where an
asymmetric carbon atom is attached to four different
ligands, and accordingly exists as two enantiomers, ESL
and its antipode R-licarbazepine acetate (BIA 2-059).8,9
ESL, R-licarbazepine acetate and their racemic mixture, as
well as other related compounds, were orally assessed in
rats for anticonvulsant activity and compared with carba-
mazepine (CBZ) and oxcarbazepine (OXC). Surprisingly,
the licarbazepine acetate enantiomers showed to possess
strikingly different anticonvulsant properties. ESL was
clearly the most potent with anticonvulsant potency similar
to CBZ and higher than OXC, while R-licarbazepine ace-
tate was almost devoid of activity and the racemic mixture
demonstrated an intermediate potency.8 These findings
suggest that such differences could be due to the stereo-
chemistry at the carbon-10 chiral center by itself or attrib-
uted to differences in their absorption, distribution, meta-
bolism or excretion processes. Therefore, Hainzl et al.9
performed some in vitro and in vivo experimental studies
with ESL and its R-enantiomer in order to get enough
pharmacokinetic data to understand their distinct pharma-
codynamic properties. Subsequently, it was found that
ESL and its stereoisomer R-licarbazepine acetate were rap-
idly hydrolyzed to their corresponding hydroxy deriva-
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tives, S-licarbazepine (S-Lic) and R-licarbazepine (R-Lic),
respectively. However, R-Lic undergoes a further oxidation
to the trans-diol metabolite, demonstrating an increased
predisposition to earlier inactivation. Indeed, the trans-diol
is an inactive metabolite also produced from the metabo-
lism of CBZ and OXC.10
Thus, ESL is being developed as a third generation to
CBZ or a second generation to OXC,11 but it is more
closely related to OXC from a metabolic point of view.
Briefly, OXC is an achiral prodrug which, in humans, is
rapidly reduced in liver to the pharmacologically active
metabolite licarbazepine or 10-hydroxy-carbazepine.12
Nevertheless, OXC first-pass reduction to licarbazepine is
stereoselective, appearing in plasma as S-Lic and R-Lic in
approximately a 4:1 enantiomeric ratio.13–15 Concerning to
the metabolism of ESL, it is not yet well established if its
deacetylation occurs in the gastrointestinal tract, in blood
instantly after absorption or in liver.9,16 In contrast, it is
well known that in humans ESL is quickly and extensively
metabolized to S-Lic (>95%) and, to a minor extent, to R-
Lic and OXC.17–19 Thereby, S-Lic is the most relevant
metabolite of ESL and OXC, exemplifying chirality preser-
vation and stereoselective metabolism, respectively. How-
ever, since low concentrations of R-Lic are also produced
from ESL, the absolute enantioselectivity in the metabo-
lism of ESL was not observed.
To date, in spite of OXC being used in clinical practice
for several years and ESL being in its final phase of clinical
trials, few studies explored the differential pharmacoki-
netics of licarbazepine enantiomers or the bi-directional
chiral inversion.9,20 As a result, taking into account the
species-dependent metabolism of OXC and ESL, in this
case among small laboratory animals, the mouse seems to
be the most relevant species to humans from a metabolic
point of view.9,17,18,19 The current study was firstly
designed to investigate the disposition and chiral inversion
of S-Lic and R-Lic, and secondly, to examine the stereose-
lectivity in the pharmacokinetics of both enantiomers after
their separate administration to mice by oral gavage.
MATERIALS AND METHODS
Chemicals
S-Lic (BIA 2-194, lot number PC020131B, 99.79% pure
by HPLC), R-Lic (BIA 2-195, lot number PC040414, 100%
pure by HPLC), OXC (lot number 97.12.17, >98% pure by
HPLC) and BIA 2-265 (lot number PC050704, 97.4% pure
by HPLC) used as internal standard (IS), were synthesized
by BIAL (Porto, Portugal) (see Fig. 1). Methanol (HPLC
grade, SDS), water milli-Q (HPLC grade, >15 MX, home-
made), acetonitrile, ethyl acetate, sodium dihydrogen
phosphate dihydrate, di-sodium hydrogen phosphate dehy-
drate and hydrochloric acid 37% were purchased from
Merck KGaA (Darmstadt, Germany). Carboxymethylcellu-
lose sodium salt for drug suspension was obtained from
Sigma (St. Louis, USA).
Animals and Experimental Design
Adult male CD-1 mice obtained from Harlan-Interfauna
(Barcelona, Spain) weighing 30–35 g were used. The ani-
mals were housed in local animal facilities, in a light (12 h
light/dark cycle) and temperature (228C 6 18C) con-
trolled environment, for at least 5 days prior to the experi-
ments. A regular chow diet (4RF21, Mucedola, Italy) and
tap water were available ad libitum before and immediately
after the drug administration.
S-Lic and R-Lic were suspended in a 0.5% carboxy-
methylcellulose aqueous solution. Groups of eight mice
per time point received a single dose of S-Lic or R-Lic (350
mg/kg) by oral gavage (0.5 ml/30 g mouse weight). Blood
samples, brain, liver and kidney tissues were taken at
0.25, 0.5, 0.75, 1, 2, 4, 6, 10, 16 and 24 h post-dose. Blood
samples were collected into heparinized tubes by decapita-
tion preceded of cervical dislocation. The plasma was sepa-
rated by centrifugation at 4000 rpm for 10 min (48C) and
stored at 2308C until analysis. After exsanguination, brain,
liver, and kidneys were quickly removed, weighed and
then homogenized (4 ml/g) in a 0.1M sodium phosphate
buffer (pH 5). The tissue homogenates were centrifuged
at 4800 rpm for 15 min (48C) and the supernatants were
also stored at 2308C until analysis.
All animal experimentation was conducted in accord-
ance with the European Directive (86/609/EEC) for the
accommodation and care of laboratory animals and the ex-
perimental procedures were approved by the Portuguese
Veterinary General Division.
Determination of Licarbazepine Enantiomers and OXC
Plasma and tissue concentrations of S-Lic, R-Lic and
OXC were determined by an enantioselective HPLC-UV-
SPE assay previously developed and validated.21 Briefly,
an aliquot of each plasma sample (250 ll) was added to
750 ll of 0.1M sodium phosphate buffer (pH 5) spiked
with 2 lg of the IS. The samples were vortex-mixed and
loaded into Waters Oasis1 HLB extraction cartridges (30
mg, 1 ml; Milford, MA), which were previously condi-
Fig. 1. Chemical structures of S-licarbazepine (S-Lic), R-licarbazepine
(R-Lic), oxcarbazepine (OXC) and BIA 2-265 used as internal standard
(IS).
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tioned with 1 ml of methanol, 1 ml of acetonitrile and 1 ml
of water/acetonitrile (95:5, v/v). After sample elution, the
loaded cartridges were submitted to 230 kPa and washed
twice with 1 ml of water and twice with 1 ml of water/ace-
tonitrile (95:5, v/v). After drying the sorbent under airflow
for 5 min, the drugs were eluted with 1 ml of ethyl acetate
under a gentle vacuum and then the cartridges were dried
for 30 sec at 230 kPa. The eluates were evaporated to dry-
ness under a nitrogen stream at 458C and the residues
reconstituted in 100 ll of water/methanol (88:12, v/v), vor-
texed for 30 sec and placed in an ultrasonic bath at room
temperature for 1 min. Following this, the reconstituted
extracts were transferred to 0.22 lm Spin-X centrifugal fil-
ters, centrifuged at 13,400 rpm for 2 min and 20 ll of the
final filtered extract were used for HPLC analysis. The
supernatants of brain, liver and kidney homogenates were
centrifuged (13,400 rpm for 20 min) a second time to give
clear supernatants of which 1 ml (250 lg of tissue) was
also spiked with 2 lg of the IS. Next the drugs in the
brain, liver, and kidney supernatants were extracted by
the solid-phase extraction procedure already described for
plasma samples, with some differences in the washing
steps and vacuum conditions (240 kPa). As tissue ma-
trices are more complex than plasma, the loaded car-
tridges were washed with 1 ml of water and 1 ml of water/
acetonitrile (95:5, v/v) three and four times in brain sam-
ples and in liver/kidney samples, respectively.
The HPLC analysis was performed on a BAS-480 Liquid
Chromatograph equipped with a PM-80 pump, a Rheodyne
manual injector with a 20-ll loop, a BAS UV-116 UV-Vis de-
tector, a BAS LC-22C Temperature Controller, a BAS DA-5
Chromatography Control and a Data System Interface (all
from Bioanalytical Systems, West Lafayette, IN). Data col-
lection and integration were achieved by means of a BAS
Chromgraph Control and Chromgraph Report software
version 2.30. The chromatographic separation was carried
out at 308C by isocratic elution with water/methanol
(88:12, v/v), at a flow rate of 0.7 ml/min, on a LiChro-
CART 250-4 ChiraDex (b-cyclodextrin, 5 lm) column pro-
tected by a LiChroCART 4-4 ChiraDex (b-cyclodextrin,
5 lm) guard column purchased from Merck KGaA (Darm-
stadt, Germany). The detector was set at 225 nm. The
method was linear for OXC over concentration ranges 0.4–
8 lg/ml in mouse plasma, 0.1–1.5 lg/ml in supernatant of
brain homogenate and 0.1–2 lg/ml in supernatant of
liver/kidney homogenates, and for each licarbazepine
enantiomer in the ranges of 0.4–80 lg/ml, 0.1–15 lg/ml
and 0.1–20 lg/ml in plasma, brain, and liver/kidney,
respectively. The precision and accuracy were lower than
15%. No peaks due to the plasma and tissues interfered at
the retention time of the analytes. The limit of quantifica-
tion (LOQ) was 0.4 lg/ml in plasma and 0.1 lg/ml (0.4
lg/g) in supernatants of tissue homogenates.
Pharmacokinetic Analysis
The peak concentration of S-Lic, R-Lic and OXC in
plasma and tissues (Cmax) and the time to reach Cmax
(tmax) were obtained directly from the experimental data.
Other pharmacokinetic parameters were computed from
the mean concentration data (n 5 8) obtained at each time
point by non-compartmental analysis using the WinNonlin1
Version 4.1 (Pharsight, Mountain View, CA): area under
the concentration-time curve (AUC) from time zero to the
last sampling time at which concentrations were at or
above the LOQ (AUC0–t), calculated by the linear trapezoi-
dal rule; AUC from time zero to infinite (AUC0–1), calcu-
lated from AUC0–t 1 (Clast/kz), where Clast is the last quan-
tifiable concentration and kz is the apparent terminal rate
constant calculated by log-linear regression of the terminal
segment of the concentration–time profile; apparent ter-
minal elimination half-life (t1/2) and mean residence
time (MRT). Mean plasma and tissue concentrations
lower than the LOQ of the assay were taken as zero for all
calculations.
RESULTS
Plasma and Brain, Liver and Kidney
Tissue Disposition of S-Lic
The mean plasma and brain, liver and kidney tissue con-
centration–time profiles of S-Lic and their metabolites
(OXC and R-Lic), following oral administration of pure S-
Lic enantiomer at 350 mg/kg to mice, are presented in
Figure 2. The corresponding pharmacokinetic parameters
estimated by non-compartmental analysis are summarized
in Table 1. The peak concentrations of S-Lic were reached
at the earliest sampling time point (0.25 h) in plasma, liver
and kidneys, demonstrating that the parent drug is rapidly
absorbed. As expected, the peak brain concentration of S-
Lic was attained later (2 h) than in plasma. Figure 2 shows
that in mice S-Lic is metabolized to a small extent with
OXC and R-Lic being its major and minor metabolites,
respectively. Indeed, following its own administration, S-
Lic corresponded to approximately 85, 77, 90 and 92% of
total drug exposure in plasma, brain, liver and kidneys,
respectively (as assessed by AUC0–1). In the same way,
the metabolite OXC represented 15, 23, 10, and 8% in the
corresponding matrices. The drug exposure to R-Lic was
substantially lower representing less than 0.24% in liver,
whereas in kidney tissue it was found in measurable
amounts just at 0.25-h post-dose, not allowing the calcula-
tion of the corresponding AUC0–1.
To assess the rate and the extent of tissue distribution
of S-Lic and its metabolites, the corresponding Cmax and
AUC0–1 tissue/plasma ratios were calculated for brain,
liver and kidneys, and are displayed in the Table 2. First
of all, the Cmax and AUC0–1 tissue/plasma ratios were not
available for R-Lic, because its plasma levels were found
below the LOQ of the analytical method. All estimated val-
ues for brain/plasma ratios were lower than the unity,
demonstrating higher plasma drug concentrations. These
data also indicated that the distribution of S-Lic into the
brain was less favorable than that for OXC. In fact, the rate
and the extension of OXC brain penetration were, respec-
tively, 2.1 and 1.7 times greater than those for S-Lic. More-
over, as shown in the Table 1, the tmax of S-Lic in the brain
was quite displaced to the right comparatively to that in
plasma, whereas for OXC the tmax in brain and in plasma
were coincident. On the other hand, in agreement with
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the values of Cmax and AUC0–1 liver and kidney/plasma
ratios, the predisposition for liver and kidney storage of S-
Lic is evident in contrast to OXC, which appeared to in a
larger extent in plasma. However, the Cmax and AUC0–1
liver/plasma ratios for S-Lic were shown to be greater
than those in kidneys, supporting that the liver will be its
main deposit.
Regarding the t1/2 and MRT parameters of all com-
pounds in all matrices (Table 1), an aspect that deserves
to be pointed out is the very low t1/2 and MRT values esti-
mated for R-Lic in liver.
Plasma and Brain, Liver and Kidney
Tissue Disposition of R-Lic
The mean plasma and brain, liver and kidney tissue con-
centration–time profiles of R-Lic and its metabolites (OXC
and S-Lic) were also determined in mice after a single oral
dose of R-Lic enantiomer at 350 mg/kg (see Fig. 3). How-
ever, it is important to stress that in addition to OXC and
S-Lic, another more polar metabolite was detected in con-
siderable amounts, which was not quantified because the
method was not validated for that purpose. Consequently,
when possible, plasma and tissue pharmacokinetic param-
eters of R-Lic, S-Lic, and OXC were calculated by non-com-
partmental model and the most relevant parameters are
summarized in Table 3. Taking into account the data pre-
sented, it is evident that the highest plasma, liver and kid-
ney R-Lic concentrations were achieved at first sampling
time point (0.25 h) and, at that moment, its brain levels
were already elevated and close to the maximal brain con-
centration (Figure 3B). Hence, these findings showed that
R-Lic is rapidly absorbed from the mouse gastrointestinal
tract and is quickly distributed. Undoubtedly, following its
oral administration to mice, R-Lic was found to be
the major compound in plasma and in all assayed tissues
over the full sampling time range. OXC and S-Lic were
Fig. 2. Mean plasma (A), brain (B), liver (C), and kidney (D) concentration–time profiles of S-Lic, R-Lic, and OXC following a single oral administra-
tion of S-Lic 350 mg/kg to mice. Symbols represent the means of eight mice.
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produced to a small extent possibly by R-Lic oxidation and
isomerization, respectively. S-Lic concentrations were
found above the LOQ of the assay in plasma, liver and kid-
neys, while OXC was quantified in all matrices.
Once again, to evaluate the rate and the extent of tissue
distribution of R-Lic and its metabolites, the corresponding
Cmax and AUC0–1 tissue/plasma ratios were estimated for
brain, liver and kidneys (Table 4). The Cmax and AUC0–1
brain/plasma ratios for R-Lic and OXC were far lower than
the unity, which support their poor penetration into the
brain. However, in spite of the extent of brain distribution
is similar for both R-Lic and OXC (as assessed by AUC0–1),
the value of the Cmax brain/plasma ratio was 3.6 times
higher for OXC, suggesting some differences in their
blood–brain barrier (BBB) crossing rate. Actually, as
shown in the Table 3, the tmax of R-Lic was observed for-
mer in plasma than in brain, whereas the tmax of OXC was
synchronized in both matrices, indicating that OXC
crosses the BBB more promptly than R-Lic. In this case,
as S-Lic brain concentrations were lower than the LOQ of
the assay, the corresponding Cmax and AUC0–1 brain/
plasma ratios could not be calculated. Taking into consid-
eration the Cmax and AUC0–1 liver/plasma ratios for the
parent compound (R-Lic), its lack of ability for accumula-
tion (ratios near the unity) is evident. In contrast, the S-Lic
formed as a metabolite of R-Lic trends towards hepatic
accumulation and the metabolite OXC undergoes hepatic
release into the systemic circulation. Likewise, the kid-
ney/plasma ratios support the renal storage of S-Lic pro-
duced but to a lesser degree than that occurring in liver.
Finally, R-Lic and OXC appeared in greater amounts in
plasma than in kidneys.
Stereoselective Distribution of S-Lic and R-Lic
The differential distribution of S-Lic and R-Lic enantio-
mers in plasma and brain, liver and kidney tissues, follow-
ing their separate administration to mice, was studied
based on their stereoselective index (enantiomeric ra-
tio),22 of the mean values of Cmax and AUC0–1 pharmaco-
kinetic parameters. Levy and Boddy22 considered a meas-
urable difference in the parameter values for a pair of
enantiomers when it is greater than or equal to 20%. In
mice treated with 350 mg/kg of S-Lic or R-Lic by oral ga-
vage, remarkable differences in the disposition of licarba-
zepine enantiomers were recorded (see Figure 4). The
AUC0–1 S/R ratios were higher than the unity in all matri-
ces, indicating a greater exposure to S-Lic than R-Lic after
equivalent dosing regime. In fact, the systemic exposure
to S-Lic and R-Lic was comparable, but even so large differ-
ences in their brain, liver and kidney exposure were identi-
fied. Indeed these data support the hepatic and renal
uptake of S-enantiomer as well as its larger distribution
(almost twice) to the brain, demonstrating the chiral dis-
crimination of S-Lic and R-Lic in a living system. More-
over, the corresponding Cmax S/R ratios of 0.66 in plasma
and 0.95 in liver and kidneys, observed at 0.25 h post-
dose, confirm an increased affinity of S-Lic to liver and kid-
ney tissues from the earliest time points.
Stereoselective Metabolism of S-Lic and
R-Lic and Chiral Inversion
Undoubtedly, analyzing the mean plasma and brain,
liver and kidney tissue concentration–time profiles
obtained after the administration of S-Lic and R-Lic to mice
(Figures 2 and 3), it is obvious that each parent compound
was the main responsible for the systemic or tissue drug
exposure. It is also evident that OXC is a common metabo-
lite produced either from S-Lic or R-Lic, which appeared in
measurable amounts in all matrices. Thus, in order to com-
pare the formation of OXC from both enantiomers, the cor-
responding Cmax and AUC0–1 ratios were calculated and
TABLE 1. Plasma, brain, liver, and kidney pharmacokinetic
parameters of S-Lic and its metabolites R-Lic and OXC in
mice after a single oral dose of S-Lic 350 mg/kg
Pharmacokinetic parameters S-Lic R-Lic OXC
Plasma
tmax (h) 0.25 NA 0.75
Cmax (lg/mL) 49.47 NA 5.65
AUC0–t (lg h/mL) 209.18 NC 39.08
AUC0–1 (lg h/mL) 310.49 NC 53.10
t1/2 (h) 9.25 NC 7.22
MRT (h) 13.60 NC 11.37
Brain
tmax (h) 2.00 NA 0.75
Cmax (lg/g) 12.56 NA 2.95
AUC0–t (lg h/g) 114.46 NC 27.20
AUC0–1 (lg h/g) 120.41 NC 35.47
t1/2 (h) 5.74 NC 7.40
MRT (h) 8.67 NC 11.01
Liver
tmax (h) 0.25 0.25 1.00
Cmax (lg/g) 71.13 0.87 6.38
AUC0–t (lg h/g) 399.55 0.95 39.08
AUC0–1 (lg h/g) 446.40 1.16 47.16
t1/2 (h) 7.18 0.82 6.87
MRT (h) 10.96 1.24 9.87
Kidney
tmax (h) 0.25 0.25 1.00
Cmax (lg/g) 51.71 0.55 3.01
AUC0–t (lg h/g) 336.89 NC 25.42
AUC0–1 (lg h/g) 375.37 NC 31.79
t1/2 (h) 7.26 NC 7.08
MRT (h) 10.62 NC 10.26
Cmax and tmax are experimental values; AUC0–t, AUC0–1, t1/2, and MRT
values were calculated by non-compartmental analysis from mean concen-
trations at each time point (n 5 8 mice per group). NA, not available; NC,
not calculated.
TABLE 2. Brain, liver, and kidney/plasma AUC0–‘ and
Cmax ratios of S-Lic, R-Lic, and OXC obtained after oral
administration of S-Lic (350 mg/kg) by oral gavage to mice
Ratio
Cmax AUC0–1
S-Lic R-Lic OXC S-Lic R-Lic OXC
Brain/plasma 0.25 NA 0.52 0.39 NA 0.67
Liver/plasma 1.44 NA 1.13 1.44 NA 0.89
Kidney/plasma 1.05 NA 0.53 1.21 NA 0.60
NA, not available.
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are represented in Figure 5. These data clearly support
that S-Lic was metabolized to OXC to a greater extent than
R-Lic. At this point it should be pointed out that the brain
exposure to OXC is approximately four times higher after
S-Lic administration. Finally, the occurrence of enantio-
meric inversion of S-Lic and R-Lic in mice should be
reported. By treatment with S-Lic, some amounts of R-Lic
were produced and following R-Lic administration its anti-
pode was also formed (Tables 1 and 3). Taking into
account the pharmacokinetic profiles obtained, a strict par-
allel was observed between the parent compounds and
their opposite enantiomer (Figures 2 and 3). Hence, these
findings suggest the ability of the mouse to perform the
interconversion of both licarbazepine enantiomers, albeit
to a small extent. To identify the preferential direction of
enantiomeric bioinversion, when possible, the Cmax and
AUC0–1 pharmacokinetic parameters of S-Lic and R-Lic
produced by administration of their complementary enan-
tiomer were compared (Table 5). As indicated, the produc-
tion of S-Lic from R-Lic was much more favorable. In fact,
the hepatic exposure to S-Lic after R-Lic administration
was approximately 40 times greater than that observed for
R-Lic following S-Lic administration (as assessed by
AUC0–1). Finally, the stereoselectivity in the metabolism
of licarbazepine enantiomers was also supported by the
formation of an additional metabolite from R-Lic.
DISCUSSION
The interest in three-dimensional molecular structure of
drugs was largely ignored during decades of pharmaceuti-
cal research, but recently, it has emerged as a key issue in
drug design, discovery, development and regulatory
fields.5 In fact, chirality is one of the main features of living
systems and the interactions of drugs with corresponding
biological targets may be stereoselective.1,2 Therefore, at
the present time, the majority of the new drugs reaching
Fig. 3. Mean plasma (A), brain (B), liver (C), and kidney (D) concentration–time profiles of R-Lic, S-Lic, and OXC following a single oral administra-
tion of R-Lic 350 mg/kg to mice. Symbols represent the means of eight mice.
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the market are single enantiomers rather than racemic
mixtures to improve the therapeutic index, given that one
of the enantiomers may be inactive or even counterproduc-
tive to the therapeutic effect.2,4
It is widely accepted that the stereochemistry has little
influence on passive processes such as diffusion across
membranes. However, when the drug interacts with an
enzyme or a transporter system the chiral discrimination
may be seen, at least, if the drug stereogenic center(s) are
important in its target interaction.23 Metabolism has been
shown to be the most important pharmacokinetic process
in enantioselective drug disposition, but plasma and tissue
protein binding as well as membrane permeability may
also play a preponderant role.24 Thereby, the liver and kid-
ney pharmacokinetic behavior of S-Lic and R-Lic enantiom-
ers and their brain uptake were investigated in mice.
These biological matrices were chosen, firstly, because
the brain is the therapeutic target of licarbazepine enan-
tiomers, and secondly, the liver and kidneys are the most
important organs from a pharmacokinetic point of view,
being respectively, the primary organ for drug metabolism
and drug excretion. In the present study, S-Lic and R-Lic
plasma protein binding were not determined due to their
low binding percentage (<30%) in dogs, which was almost
identical for both enantiomers.20 In humans, the licarbaze-
pine plasma protein binding was found to be 40%.12,15
Our results demonstrated that S-Lic and R-Lic are rap-
idly absorbed from the mouse gastrointestinal tract and
rapidly distributed after their own administration, at least
for the highly perfused tissues. From the overall data
obtained, the enantioselectivity in licarbazepine absorption
appears to be unlikely, because the liver concentrations of
TABLE 3. Plasma, brain, liver, and kidney pharmacokinetic
parameters of R-Lic and its metabolites S-Lic and OXC in
mice after a single oral dose of R-Lic 350 mg/kg
Pharmacokinetic parameters R-Lic S-Lic OXC
Plasma
tmax (h) 0.25 0.25 0.75
Cmax (lg/mL) 74.55 1.09 4.43
AUC0–t (lg h/mL) 237.22 4.16 34.69
AUC0–1 (lg h/mL) 282.68 11.67 42.21
t1/2 (h) 12.24 8.98 8.47
MRT (h) 12.30 13.21 12.54
Brain
tmax (h) 0.75 NA 0.75
Cmax (lg/g) 8.76 NA 1.89
AUC0–t (lg h/g) 57.21 NC 6.81
AUC0–1 (lg h/g) 64.38 NC 9.10
t1/2 (h) 7.63 NC 3.25
MRT (h) 10.27 NC 4.62
Liver
tmax (h) 0.25 0.25 0.75
Cmax (lg/g) 74.96 5.24 3.59
AUC0–t (lg h/g) 235.88 36.76 14.05
AUC0–1 (lg h/g) 263.44 46.25 18.04
t1/2 (h) 6.74 9.06 6.14
MRT (h) 9.98 14.03 9.38
Kidney
tmax (h) 0.25 0.25 0.75
Cmax (lg/g) 54.62 2.52 3.66
AUC0–t (lg h/g) 194.11 12.52 12.05
AUC0–1 (lg h/g) 227.96 15.43 16.28
t1/2 (h) 9.18 4.16 4.56
MRT (h) 11.59 5.92 6.99
Cmax and tmax are experimental values; AUC0–t, AUC0–1, t1/2 and MRT val-
ues were calculated by non-compartmental analysis from mean concentra-
tions at each time point (n 5 8 mice per group); NA, not available; NC,
not calculated.
TABLE 4. Brain, liver, and kidney/plasma AUC0–‘ and
Cmax ratios of R-Lic, S-Lic and OXC obtained after oral
administration of R-Lic (350 mg/kg) by oral gavage to mice
Ratio
Cmax AUC0–1
R-Lic S-Lic OXC R-Lic S-Lic OXC
Brain/plasma 0.12 NA 0.43 0.23 NA 0.22
Liver/plasma 1.01 4.81 0.81 0.93 3.96 0.43
Kidney/plasma 0.73 2.31 0.83 0.81 1.32 0.39
NA, not available.
Fig. 4. The Cmax and AUC0–1 S/R enantiomeric ratios of S-Lic and R-
Lic in plasma and brain, liver and kidney tissues after their separate
administration (350 mg/kg) to mice by oral gavage.
Fig. 5. The Cmax and AUC0–1 OXC ratios in plasma and brain, liver
and kidney tissues after separate administration of S-Lic and R-Lic (350
mg/kg) to mice by oral gavage.
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both enantiomers after their separate administration are
similar at first sampling time point (0.25 h). However, at
that time, the value of the stereoselective index (1.51)
between R-Lic and S-Lic plasma concentrations already
reflect their stereoselective first-pass effect. It was demon-
strated that S-Lic undergoes hepatic and renal accumula-
tion either after its own administration or when formed as
a metabolite of R-Lic. Hence, liver and kidneys act like res-
ervoirs of S-Lic. From the metabolic data, it is also evident
that OXC was produced from both licarbazepine enantio-
mers, being generated to a higher extent from S-Lic. How-
ever, less obvious may be the source of the small amounts
of S-Lic and R-Lic produced following the administration of
the corresponding antipode. At this moment, it is impor-
tant to consider that the reduction of OXC not occurs
effectively in mice, in contrast to man.9 Moreover, the tmax
values were coincident for both administered and pro-
duced licarbazepine enantiomers, whereas the tmax for
OXC occurred later. Consequently, the bi-directional chiral
inversion of licarbazepine enantiomers occurred in mice
probably through a liver racemase, which favors the pro-
duction of S-Lic from R-Lic, and not through OXC reduc-
tion. In fact, the chiral inversion is always mediated by
enzymes and, in humans, was firstly demonstrated with
ibuprofen.25 The extra metabolite produced in mice after
treatment with R-Lic, most likely, will correspond to the
trans-diol. These results are in agreement with the obser-
vations performed by Hainzl et al.9 demonstrating that the
trans-diol is only produced from R-Lic. The formation of
the trans-diol will probably contribute to an earlier inactiva-
tion of R-Lic. After all, taking into consideration the data
presented and the information provided by Hainzl et al.,9
the proposed metabolic pathways for S-Lic and R-Lic in
mice are represented in Figure 6.
From this work, another relevant part of data was the
stereoselective brain disposition of S- and R-Lic enantio-
mers. To our knowledge, these findings are reported here
for the first time. Although their comparable systemic ex-
posure (AUC0–1 S/R plasma ratio close to unity), the
extent of brain penetration for S-Lic was found to be
approximately 2 times greater than that for R-Lic. Indeed,
as other central nervous system drugs, S-Lic and R-Lic
must overcome the BBB to reach the brain parenchyma,
with their brain concentrations being much lower than
those in plasma. Actually, the BBB consists of various
transporter proteins involved in the active influx and efflux
of drugs to and from the brain.26 Thus, as with other
drugs, licarbazepine enantiomers may be substrates for
multidrug transporters (MDT) including P-glycoprotein at
the BBB,27 being subject to efflux transport and, possibly,
R-Lic will be the preferential substrate. Previously, Clinck-
ers et al.28 demonstrated that OXC is a substrate for MDT
at the BBB, which actively limits the penetration and accu-
mulation of OXC into the brain.
In 1991, Levy and Boddy22 considered three distinct
organizational levels in the body (macromolecular, whole-
organ and whole-body) and suggested that degree of ste-
reoselectivity is more pronounced and easier to detect in
front of macromolecular-specific or organ-specific parame-
ters than in whole-body pharmacokinetic parameters.
Indeed, our data appear to reflect this general theory: first
of all an additional metabolite was formed from R-Lic,
detecting stereoselectivity in the presence of metabolic
enzymes; secondly, considering the AUC0–1 pharmacoki-
netic parameter, the stereoselectivity between S- and R-Lic
was greater in whole-organ level (brain, liver, and kidney)
than in whole-body (see Fig. 4).
Despite the obvious species differences between mouse
and man, these data give new information related to the
pharmacokinetic disposition of licarbazepine enantiomers
and their ability to cross the BBB and attain their thera-
peutic target. At last, the stereoselectivity identified in the
disposition of S-Lic and R-Lic may also explain the differ-
ences observed in the systemic drug exposure to ESL and
OXC. Indeed, Bialer et al.29 reported that the bioavailabil-
ity of ESL, measured in terms of S-Lic and R-Lic AUC, was
16% greater than that for OXC after intake of an equivalent
molar dose.
TABLE 5. Enantiomeric interconversion of S-Lic and
R-Lic after their separate administration to mice by








S-Lic(R-Lic), S-Lic produced from R-Lic; R-Lic(S-Lic), R-Lic produced from S-
Lic; NA, not available.
Fig. 6. Proposed metabolism of S-Lic and R-Lic in mice. The thickness
of the arrows indicates the relative extent of the metabolic pathways: OXC
is the major metabolite of S-Lic (1) and R-Lic (2), enantiomeric inversion
is favorable to the formation of S-Lic (3) and conjugating the data of this
study with the findings reported by Hainzl et al.9 the trans-diol metabolite
is produced only from R-Lic (4).
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